二肽基肽酶4抑制剂使用与糖尿病患者大疱性类天疱疮风险的关联
这项回顾性、全国性、基于人群的病例对照研究使用韩国医保理赔数据(2012年1月1日至2016年12月31日),纳入670例糖尿病合并大疱性类天疱疮(BP)患者和670例仅患糖尿病的对照。使用二肽基肽酶4(DPP-4)抑制剂与BP风险显著增加相关(aOR 1.58,95%CI 1.25-2.00,P<.001),其中维格列汀风险最高(aOR 1.81,95%CI 1.31-2.50,P<.001)。作者认为DPP-4抑制剂尤其维格列汀可能与糖尿病患者BP发生相关。
要点
- 使用DPP-4抑制剂与糖尿病患者的BP风险显著增加相关(aOR 1.58,95%CI 1.25-2.00,P<.001)。
- 在韩国可用的DPP-4抑制剂中,维格列汀关联的aOR最高(aOR 1.81,95%CI 1.31-2.50,P<.001)。
- 亚组分析显示男性患者中关联显著(aOR 1.91,95%CI 1.39-2.63,P<.001),且维格列汀风险最高(aOR 2.70,95%CI 1.73-4.34,P<.001)。
核心结论
- 研究提示DPP-4抑制剂与糖尿病患者发生BP的风险显著增加相关。
- 在韩国可用的DPP-4抑制剂中,维格列汀关联的风险最高,尤其在男性患者中。
- 作者认为,从业者应考虑DPP-4抑制剂尤其维格列汀可能与糖尿病患者BP发生相关,这些全国性人群结果可作为进一步研究的基础。
研究设计与样本
- 采用韩国医保理赔数据(2012年1月1日至2016年12月31日)的回顾性、全国性、基于人群的病例对照研究。
- 纳入新诊断BP且患糖尿病的患者670例,并按年龄、性别和诊断年份匹配随机选取仅患糖尿病的对照670例。
- 两组平均(标准差)年龄均为75.3(10.0)岁,每组男性均为342例(51.0%)。
主要发现
- 研究期间糖尿病合并BP患者数从2012年的77例增至2016年的206例,增加超过一倍。
- 全部BP患者中糖尿病患者的比例从2012年的0.18上升至2016年的0.33。
- 使用DPP-4抑制剂与BP风险显著增加相关(aOR 1.58,95%CI 1.25-2.00,P<.001)。
- 在韩国使用的所有DPP-4抑制剂中,维格列汀关联的aOR最高(aOR 1.81,95%CI 1.31-2.50,P<.001)。
- 亚组分析显示男性患者中关联显著(aOR 1.91,95%CI 1.39-2.63,P<.001),且维格列汀风险最高(aOR 2.70,95%CI 1.73-4.34,P<.001)。
关键数值与推荐
- 使用DPP-4抑制剂与BP风险显著增加相关(aOR 1.58,95%CI 1.25-2.00,P<.001)。
- 维格列汀关联的aOR为1.81(95%CI 1.31-2.50,P<.001),在韩国DPP-4抑制剂中最高。
- 男性亚组中DPP-4抑制剂关联aOR为1.91(95%CI 1.39-2.63,P<.001),维格列汀aOR为2.70(95%CI 1.73-4.34,P<.001)。
临床怎么用
- 作者认为,从业者应考虑DPP-4抑制剂尤其维格列汀可能与糖尿病患者BP发生相关。
- 作者指出这些全国性人群结果可作为进一步研究的基础,以了解DPP-4抑制剂如何促成BP发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Recent studies suggest that dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with an increased risk of developing bullous pemphigoid (BP). Population-based studies on the association between DPP-4 inhibitors and BP are limited. OBJECTIVE: To characterize the potential association between the use of DPP-4 inhibitors and an increased risk of developing BP. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, nationwide, population-based, case-control study using Korean insurance claims data from January 1, 2012, to December 31, 2016, included patients with newly diagnosed BP and diabetes. Control patients with diabetes (and without BP) were randomly obtained after matching for age, sex, and year of diagnosis within the same period. MAIN OUTCOMES AND MEASURES: The number of patients with newly diagnosed BP and diabetes per year and annual changes in the proportion of patients with diabetes among all patients with BP were measured. The association between use of DPP-4 inhibitors and risk of developing BP was analyzed using univariate and multivariate logistic regression analyses. RESULTS: The study included 670 case patients (with diabetes and BP) and 670 control patients (with only diabetes) (mean [SD] age, 75.3 [10.0] years in each group; 342 [51.0%] male in each group). The number of patients with diabetes and BP more than doubled during the study period (from 77 in 2012 to 206 in 2016). The proportion of patients with diabetes among all patients with BP also increased (from 0.18 in 2012 to 0.33 in 2016). The use of DPP-4 inhibitors was associated with a significant increase in the risk of developing BP (adjusted odds ratio [aOR], 1.58; 95% CI, 1.25-2.00; P < .001); among all DPP-4 inhibitors used in Korea, the highest aOR was associated with the use of vildagliptin (aOR, 1.81; 95% CI, 1.31-2.50; P < .001). Subgroup analyses revealed a significant association in male patients (aOR, 1.91; 95% CI, 1.39-2.63; P < .001) and that vildagliptin was the most high-risk DPP-4 inhibitor (aOR, 2.70; 95% CI, 1.73-4.34; P < .001). CONCLUSIONS AND RELEVANCE: The findings suggest that DPP-4 inhibitors are associated with a significantly increased risk of the development of BP in patients with diabetes. Of the DPP-4 inhibitors available in Korea, vildagliptin was associated with the highest risk, particularly in male patients. Practitioners should consider that DPP-4 inhibitors, particularly vildagliptin, may be associated with the development of BP in patients with diabetes. These nationwide, population-based results may serve as a foundation for further studies seeking to understand how DPP-4 inhibitors contribute to the development of BP.
引用
- Lee SG, Lee HJ, Yoon MS, et al. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. JAMA Dermatol. 2019. PMID: 30624566. doi:10.1001/jamadermatol.2018.4556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。